Skip to main content
Top
Published in: Current Rheumatology Reports 6/2010

Open Access 01-12-2010

Pathophysiology of ANCA-Associated Small Vessel Vasculitis

Author: Cees G. M. Kallenberg

Published in: Current Rheumatology Reports | Issue 6/2010

Login to get access

Abstract

Antineutrophil cytoplasmic autoantibodies (ANCAs) directed to proteinase 3 (PR3-ANCA) or myeloperoxidase (MPO-ANCA) are strongly associated with the ANCA-associated vasculitides—Wegener’s granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome. Clinical observations, including the efficacy of B-cell depletion via rituximab treatment, support—but do not prove—a pathogenic role for ANCA in the ANCA-associated vasculitides. In vitro experimental studies show that the interplay of ANCA, neutrophils, the alternative pathway of the complement system, and endothelial cells could result in lysis of the endothelium. A pathogenic role for MPO-ANCA is strongly supported by in vivo experimental studies in mice and rats, which also elucidate the pathogenic mechanisms involved in lesion development. Unfortunately, an animal model for PR3-ANCA–associated Wegener’s granulomatosis is not yet available. Here, cellular immunity appears to play a major role as well, particularly via interleukin-17–producing T cells, in line with granulomatous inflammation in the lesions. Finally, microbial factors, in particular Staphylococcus aureus and gram-negative bacteria, seem to be involved in disease induction and expression, but further studies are needed to define their precise role in disease development.
Literature
1.
go back to reference Kallenberg CG, Heeringa P, Stegeman CA: Mechanisms of disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol 2006, 2:661–670.CrossRefPubMed Kallenberg CG, Heeringa P, Stegeman CA: Mechanisms of disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol 2006, 2:661–670.CrossRefPubMed
2.
go back to reference Kallenberg CGM: Churg-Strauss syndrome: just one disease entity? Arthritis Rheum 2005, 52:2589–2593.CrossRefPubMed Kallenberg CGM: Churg-Strauss syndrome: just one disease entity? Arthritis Rheum 2005, 52:2589–2593.CrossRefPubMed
3.
go back to reference Boomsma MM, Stegeman CA, van der Leij MJ, et al.: Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000, 43:2025–2033.CrossRefPubMed Boomsma MM, Stegeman CA, van der Leij MJ, et al.: Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000, 43:2025–2033.CrossRefPubMed
4.
go back to reference Finkielman JD, Merkel PA, Schroeder D, et al.: Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007, 147:611–619.PubMed Finkielman JD, Merkel PA, Schroeder D, et al.: Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007, 147:611–619.PubMed
5.
go back to reference Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group: Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 2005, 352:351–361.CrossRef Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group: Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 2005, 352:351–361.CrossRef
6.
go back to reference Stegeman CA, Cohen Tervaert JW, Sluiter WJ, et al.: Association of nasal carriage of Staphylococcus aureus and higher relapse in Wegener’s granulomatosis. Ann Intern Med 1994, 120:12–17.PubMed Stegeman CA, Cohen Tervaert JW, Sluiter WJ, et al.: Association of nasal carriage of Staphylococcus aureus and higher relapse in Wegener’s granulomatosis. Ann Intern Med 1994, 120:12–17.PubMed
7.
go back to reference Sanders JS, Slot MC, Stegeman CA: Maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003, 349:2072–2073.CrossRefPubMed Sanders JS, Slot MC, Stegeman CA: Maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003, 349:2072–2073.CrossRefPubMed
8.
go back to reference •Stone JH, Merkel PA, Spiera R, et al.: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363:221–232. This large randomized controlled trial demonstrated that rituximab is as effective as oral cyclophosphamide for induction of remission in patients with severe ANCA-associated vasculitis and could even be more effective than oral cyclophosphamide in relapsing patients. Given the long-term toxicity of oral cyclophosphamide, the results of this study may change current practice in the treatment of ANCA-associated vasculitis. CrossRefPubMed •Stone JH, Merkel PA, Spiera R, et al.: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363:221–232. This large randomized controlled trial demonstrated that rituximab is as effective as oral cyclophosphamide for induction of remission in patients with severe ANCA-associated vasculitis and could even be more effective than oral cyclophosphamide in relapsing patients. Given the long-term toxicity of oral cyclophosphamide, the results of this study may change current practice in the treatment of ANCA-associated vasculitis. CrossRefPubMed
9.
go back to reference •Jones RB, Cohen Tervaert JW, Hauser T, et al.: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363:211–220. This study showed that rituximab is as effective as pulse intravenous cyclophosphamide in patients with ANCA-associated vasculitis with severe renal involvement. It confirms and extends the data from the study by Stone et al. [8•] and suggests that rituximab could be first choice for induction treatment of ANCA-associated vasculitis. CrossRefPubMed •Jones RB, Cohen Tervaert JW, Hauser T, et al.: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363:211–220. This study showed that rituximab is as effective as pulse intravenous cyclophosphamide in patients with ANCA-associated vasculitis with severe renal involvement. It confirms and extends the data from the study by Stone et al. [8•] and suggests that rituximab could be first choice for induction treatment of ANCA-associated vasculitis. CrossRefPubMed
10.
go back to reference Bansal PJ, Tobin MC: Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 2004, 93:398–401.CrossRefPubMed Bansal PJ, Tobin MC: Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 2004, 93:398–401.CrossRefPubMed
11.
go back to reference Falk RJ, Terrell R, Charles LA, Jennette JC: Antineutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals. Proc Natl Acad Sci U S A 1990, 87:4115–4119.CrossRefPubMed Falk RJ, Terrell R, Charles LA, Jennette JC: Antineutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals. Proc Natl Acad Sci U S A 1990, 87:4115–4119.CrossRefPubMed
12.
go back to reference Rarok AA, Limburg PC, Kallenberg CGM: Neutrophil-activating potential of antineutrophil cytoplasm autoantibodies. J Leukoc Biol 2003, 74:3–15.CrossRefPubMed Rarok AA, Limburg PC, Kallenberg CGM: Neutrophil-activating potential of antineutrophil cytoplasm autoantibodies. J Leukoc Biol 2003, 74:3–15.CrossRefPubMed
13.
go back to reference •Schreiber A, Rolle S, Peripelittchenko L, et al.: Phosphoinositol 3-kinase-gamma mediates antineutrophil cytoplasmic autoantibody-induced glomerulonephritis. Kidney Int 2010, 77:118–128. This study is built on prior observations that ANCA-induced neutrophil activation is a fundamental pathophysiologic mechanism in MPO-ANCA–associated vasculitis. Interfering in this mechanism by blocking the action of the enzyme phosphoinositol 3-kinase–γ inhibited the development of disease in an animal model of MPO-ANCA–associated glomerulonephritis. Inhibitors of this enzyme, which have been developed, could be used in clinical practice. CrossRefPubMed •Schreiber A, Rolle S, Peripelittchenko L, et al.: Phosphoinositol 3-kinase-gamma mediates antineutrophil cytoplasmic autoantibody-induced glomerulonephritis. Kidney Int 2010, 77:118–128. This study is built on prior observations that ANCA-induced neutrophil activation is a fundamental pathophysiologic mechanism in MPO-ANCA–associated vasculitis. Interfering in this mechanism by blocking the action of the enzyme phosphoinositol 3-kinase–γ inhibited the development of disease in an animal model of MPO-ANCA–associated glomerulonephritis. Inhibitors of this enzyme, which have been developed, could be used in clinical practice. CrossRefPubMed
14.
go back to reference •Schreiber A, Xiao H, Jennette JC, et al.: C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 2009, 20:289–298. Blocking the interaction between complement C5a and its receptor could abrogate lesion development in an animal model of MPO-ANCA glomerulonephritis. As monoclonal antibodies to C5a are clinically available, interfering in this process could be a novel treatment of ANCA-associated vasculitis. CrossRefPubMed •Schreiber A, Xiao H, Jennette JC, et al.: C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 2009, 20:289–298. Blocking the interaction between complement C5a and its receptor could abrogate lesion development in an animal model of MPO-ANCA glomerulonephritis. As monoclonal antibodies to C5a are clinically available, interfering in this process could be a novel treatment of ANCA-associated vasculitis. CrossRefPubMed
15.
go back to reference Xing GQ, Chen M, Liu G, et al.: Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol 2009, 29:282–291.CrossRefPubMed Xing GQ, Chen M, Liu G, et al.: Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol 2009, 29:282–291.CrossRefPubMed
16.
go back to reference Ewert BH, Jennette JC, Falk RJ: Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int 1992, 41:375–383.CrossRefPubMed Ewert BH, Jennette JC, Falk RJ: Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int 1992, 41:375–383.CrossRefPubMed
17.
go back to reference Radford DJ, Savage CO, Nash GB: Treatment of rolling neutrophils with antineutrophil cytoplasmic antibodies causes conversion to firm integrin-mediated adhesion. Arthritis Rheum 2000, 43:1337–1345.CrossRefPubMed Radford DJ, Savage CO, Nash GB: Treatment of rolling neutrophils with antineutrophil cytoplasmic antibodies causes conversion to firm integrin-mediated adhesion. Arthritis Rheum 2000, 43:1337–1345.CrossRefPubMed
18.
go back to reference Nolan SL, Kalia N, Nash GB, et al.: Mechanisms of ANCA-mediated leukocyte-endothelial cell interactions in vivo. J Am Soc Nephrol 2008, 19:973–984.CrossRefPubMed Nolan SL, Kalia N, Nash GB, et al.: Mechanisms of ANCA-mediated leukocyte-endothelial cell interactions in vivo. J Am Soc Nephrol 2008, 19:973–984.CrossRefPubMed
19.
go back to reference •Kessenbrock K, Krumbholz M, Schönermarck U, et al.: Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009, 15:623–625. The authors present a new mechanism for the pathogenic role of ANCA-induced neutrophil activation. The antibodies induce formation of NETs. These NETs containing PR3 and MPO may not only trigger vasculitis in the kidneys but may also promote the autoimmune response to PR3 and MPO. CrossRefPubMed •Kessenbrock K, Krumbholz M, Schönermarck U, et al.: Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009, 15:623–625. The authors present a new mechanism for the pathogenic role of ANCA-induced neutrophil activation. The antibodies induce formation of NETs. These NETs containing PR3 and MPO may not only trigger vasculitis in the kidneys but may also promote the autoimmune response to PR3 and MPO. CrossRefPubMed
20.
go back to reference Xiao H, Heeringa P, Hu P, et al.: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002, 110:955–963.PubMed Xiao H, Heeringa P, Hu P, et al.: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002, 110:955–963.PubMed
21.
go back to reference Huugen D, Xiao H, van Esch A, et al.: Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol 2005, 167:47–58.PubMed Huugen D, Xiao H, van Esch A, et al.: Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol 2005, 167:47–58.PubMed
22.
go back to reference Xiao H, Heeringa P, Liu Z, et al.: The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol 2005, 167:39–45.PubMed Xiao H, Heeringa P, Liu Z, et al.: The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol 2005, 167:39–45.PubMed
23.
go back to reference Schreiber A, Xiao H, Falk RJ, Jennette JC: Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies. J Am Soc Nephrol 2006, 17:3355–3364.CrossRefPubMed Schreiber A, Xiao H, Falk RJ, Jennette JC: Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies. J Am Soc Nephrol 2006, 17:3355–3364.CrossRefPubMed
24.
go back to reference Xiao H, Schreiber A, Heeringa P, et al.: Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 2007, 170:52–64.CrossRefPubMed Xiao H, Schreiber A, Heeringa P, et al.: Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 2007, 170:52–64.CrossRefPubMed
25.
go back to reference •van Timmeren MM, van der Veen BS, Stegeman CA, et al.: IgG glycan hydrolysis attenuates ANCA-mediated glomerulonephritis. J Am Soc Nephrol 2010, 21:1103–1114. The authors showed that modulation of IgG glycosylation with the bacterial enzyme Endo S can prevent induction and mitigate disease expression in an animal model of MPO-ANCA–associated glomerulonephritis. This could be a potential new approach in the treatment of ANCA-associated vasculitis. CrossRefPubMed •van Timmeren MM, van der Veen BS, Stegeman CA, et al.: IgG glycan hydrolysis attenuates ANCA-mediated glomerulonephritis. J Am Soc Nephrol 2010, 21:1103–1114. The authors showed that modulation of IgG glycosylation with the bacterial enzyme Endo S can prevent induction and mitigate disease expression in an animal model of MPO-ANCA–associated glomerulonephritis. This could be a potential new approach in the treatment of ANCA-associated vasculitis. CrossRefPubMed
26.
go back to reference Little MA, Smyth CL, Yadav R, et al.: Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 2005, 106:2050–2058.CrossRefPubMed Little MA, Smyth CL, Yadav R, et al.: Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 2005, 106:2050–2058.CrossRefPubMed
27.
go back to reference Pfister H, Ollert M, Fröhlich LF, et al.: Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 2004, 104:1411–1418.CrossRefPubMed Pfister H, Ollert M, Fröhlich LF, et al.: Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 2004, 104:1411–1418.CrossRefPubMed
28.
go back to reference van der Geld YM, Hellmark T, Selga D, et al.: Rats and mice immunized with chimeric human/mouse proteinase 3 produce autoantibodies to mouse Pr3 and rat granulocytes. Ann Rheum Dis 2007, 66:1679–1682.CrossRefPubMed van der Geld YM, Hellmark T, Selga D, et al.: Rats and mice immunized with chimeric human/mouse proteinase 3 produce autoantibodies to mouse Pr3 and rat granulocytes. Ann Rheum Dis 2007, 66:1679–1682.CrossRefPubMed
29.
go back to reference Pendergraft WF 3rd, Preston GA, Shah RR, et al.: Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 2004, 10:72–79.CrossRefPubMed Pendergraft WF 3rd, Preston GA, Shah RR, et al.: Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 2004, 10:72–79.CrossRefPubMed
30.
go back to reference Yang JM, Bautz DJ, Lionaki S, et al.: ANCA patients have T cells responsive to complementary PR-3 antigen. Kidney Int 2008, 74:1159–1169.CrossRefPubMed Yang JM, Bautz DJ, Lionaki S, et al.: ANCA patients have T cells responsive to complementary PR-3 antigen. Kidney Int 2008, 74:1159–1169.CrossRefPubMed
31.
go back to reference •Kain R, Exner M, Brandes R, et al.: Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008, 14:1088–1096. The authors presented a new autoantibody directed to hLAMP-2 in pauci-immune necrotizing glomerulonephritis that is highly sensitive and specific for this condition. Most interestingly, they showed that immunization with an adhesion from gram-negative bacteria, by molecular mimicry, induces antibodies to hLAMP-2 that were pathogenic in in vitro and in vivo experiments. CrossRefPubMed •Kain R, Exner M, Brandes R, et al.: Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008, 14:1088–1096. The authors presented a new autoantibody directed to hLAMP-2 in pauci-immune necrotizing glomerulonephritis that is highly sensitive and specific for this condition. Most interestingly, they showed that immunization with an adhesion from gram-negative bacteria, by molecular mimicry, induces antibodies to hLAMP-2 that were pathogenic in in vitro and in vivo experiments. CrossRefPubMed
32.
go back to reference Kain R, Matsui K, Exner M, et al.: A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: the lysosomal membrane glycoprotein h-LAMP-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells. J Exp Med 1995, 181:585–597.CrossRefPubMed Kain R, Matsui K, Exner M, et al.: A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: the lysosomal membrane glycoprotein h-LAMP-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells. J Exp Med 1995, 181:585–597.CrossRefPubMed
33.
go back to reference Kallenberg CG, Stegeman CA, Heeringa P: Autoantibodies vex the vasculature. Nat Med 2008, 14:1018–1019.CrossRefPubMed Kallenberg CG, Stegeman CA, Heeringa P: Autoantibodies vex the vasculature. Nat Med 2008, 14:1018–1019.CrossRefPubMed
34.
go back to reference Holle JU, Gross WL, Holl-Ulrich K, et al.: Prospective long-term follow-up of patients with localised Wegener’s granulomatosis: does it occur as persistent disease stage? Ann Rheum Dis 2010 May 28 (Epub ahead of print). Holle JU, Gross WL, Holl-Ulrich K, et al.: Prospective long-term follow-up of patients with localised Wegener’s granulomatosis: does it occur as persistent disease stage? Ann Rheum Dis 2010 May 28 (Epub ahead of print).
35.
go back to reference Abdulahad WH, van der Geld YM, Stegeman CA, Kallenberg CG: Persistent expansion of CD4+ effector memory T cells in Wegener’s granulomatosis. Kidney Int 2006, 70:938–947.CrossRefPubMed Abdulahad WH, van der Geld YM, Stegeman CA, Kallenberg CG: Persistent expansion of CD4+ effector memory T cells in Wegener’s granulomatosis. Kidney Int 2006, 70:938–947.CrossRefPubMed
36.
go back to reference Lamprecht P, Wieczorek S, Epplen JT, et al.: Granuloma formation in ANCA-associated vasculitides. APMIS Suppl 2009, 127:32–36.CrossRefPubMed Lamprecht P, Wieczorek S, Epplen JT, et al.: Granuloma formation in ANCA-associated vasculitides. APMIS Suppl 2009, 127:32–36.CrossRefPubMed
37.
go back to reference •Abdulahad WH, Kallenberg CG, Limburg PC, Stegeman CA: Urinary CD4+ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009, 60:2830–2838. This study shows that CD4 + effector memory cells are present in the urine of patients with active renal involvement in ANCA-associated vasculitis. This may enable a diagnosis of active renal disease in this condition without doing a renal biopsy. CrossRefPubMed •Abdulahad WH, Kallenberg CG, Limburg PC, Stegeman CA: Urinary CD4+ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009, 60:2830–2838. This study shows that CD4 + effector memory cells are present in the urine of patients with active renal involvement in ANCA-associated vasculitis. This may enable a diagnosis of active renal disease in this condition without doing a renal biopsy. CrossRefPubMed
38.
go back to reference Abdulahad WH, Stegeman CA, Limburg PC, Kallenberg CG: Skewed distribution of Th17 lymphocytes in patients with Wegener’s granulomatosis in remission. Arthritis Rheum 2008, 58:2196–2205.CrossRefPubMed Abdulahad WH, Stegeman CA, Limburg PC, Kallenberg CG: Skewed distribution of Th17 lymphocytes in patients with Wegener’s granulomatosis in remission. Arthritis Rheum 2008, 58:2196–2205.CrossRefPubMed
39.
go back to reference Nogueira E, Hamour S, Sawant D, et al.: Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2010, 25:2209–2217.CrossRefPubMed Nogueira E, Hamour S, Sawant D, et al.: Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2010, 25:2209–2217.CrossRefPubMed
40.
go back to reference •Gan PY, Steinmetz OM, Tan DS, et al.: Th17 cells promote autoimmune anti-myeloperoxidase glomerulonephritis. J Am Soc Nephrol 2010, 21:925–931. Th17 cells have been proposed as major effector cells in autoimmune disease. Here, the authors showed that IL-17A is instrumental in the pathophysiology of experimental MPO-ANCA glomerulonephritis. Targeting IL-17 may be a promising approach. CrossRefPubMed •Gan PY, Steinmetz OM, Tan DS, et al.: Th17 cells promote autoimmune anti-myeloperoxidase glomerulonephritis. J Am Soc Nephrol 2010, 21:925–931. Th17 cells have been proposed as major effector cells in autoimmune disease. Here, the authors showed that IL-17A is instrumental in the pathophysiology of experimental MPO-ANCA glomerulonephritis. Targeting IL-17 may be a promising approach. CrossRefPubMed
41.
go back to reference •McKinney EF, Lyons PA, Carr EJ, et al.: A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med 2010, 16:586–591. This study shows that the transcription signature of CD8 + T cells can predict prognosis in patients with ANCA-associated vasculitis and SLE. This may allow a more individualized therapeutic approach in patients with these diseases. CrossRefPubMed •McKinney EF, Lyons PA, Carr EJ, et al.: A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med 2010, 16:586–591. This study shows that the transcription signature of CD8 + T cells can predict prognosis in patients with ANCA-associated vasculitis and SLE. This may allow a more individualized therapeutic approach in patients with these diseases. CrossRefPubMed
42.
go back to reference Abdulahad WH, Stegeman CA, van der Geld YM, et al.: Functional defect of circulating regulatory CD4+ T cells in patients with Wegener’s granulomatosis in remission. Arthritis Rheum 2007, 56:2080–2091.CrossRefPubMed Abdulahad WH, Stegeman CA, van der Geld YM, et al.: Functional defect of circulating regulatory CD4+ T cells in patients with Wegener’s granulomatosis in remission. Arthritis Rheum 2007, 56:2080–2091.CrossRefPubMed
43.
go back to reference Morgan MD, Day CJ, Piper KP, et al.: Patients with Wegener’s granulomatosis demonstrate a relative deficiency and functional impairment of T-regulatory cells. Immunology 2010, 130:64–73.CrossRefPubMed Morgan MD, Day CJ, Piper KP, et al.: Patients with Wegener’s granulomatosis demonstrate a relative deficiency and functional impairment of T-regulatory cells. Immunology 2010, 130:64–73.CrossRefPubMed
44.
go back to reference Wieczorek S, Holle JU, Epplen JT: Recent progress in the genetics of Wegener’s granulomatosis and Churg-Strauss syndrome. Curr Opin Rheumatol 2010, 22:8–14.CrossRefPubMed Wieczorek S, Holle JU, Epplen JT: Recent progress in the genetics of Wegener’s granulomatosis and Churg-Strauss syndrome. Curr Opin Rheumatol 2010, 22:8–14.CrossRefPubMed
45.
go back to reference Hogan SL, Cooper GS, Savitz DA, et al.: Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based, case-control study. Clin J Am Soc Nephrol 2007, 2:290–299.CrossRefPubMed Hogan SL, Cooper GS, Savitz DA, et al.: Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based, case-control study. Clin J Am Soc Nephrol 2007, 2:290–299.CrossRefPubMed
46.
go back to reference Stegeman CA, Cohen Tervaert JW, de Jong PE, Kallenberg CGM: Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996, 335:16–20.CrossRefPubMed Stegeman CA, Cohen Tervaert JW, de Jong PE, Kallenberg CGM: Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996, 335:16–20.CrossRefPubMed
47.
go back to reference Popa ER, Stegeman CA, Kallenberg CGM, Cohen Tervaert JW: Staphylococcus aureus and Wegener’s granulomatosus. Arthritis Res 2002, 4:77–79.CrossRefPubMed Popa ER, Stegeman CA, Kallenberg CGM, Cohen Tervaert JW: Staphylococcus aureus and Wegener’s granulomatosus. Arthritis Res 2002, 4:77–79.CrossRefPubMed
48.
go back to reference Abdulahad WH, Stegeman CA, Kallenberg CGM: The role of CD4+ T cells in ANCA-associated systemic vasculitis. Nephrology 2009, 14:26–32.CrossRefPubMed Abdulahad WH, Stegeman CA, Kallenberg CGM: The role of CD4+ T cells in ANCA-associated systemic vasculitis. Nephrology 2009, 14:26–32.CrossRefPubMed
Metadata
Title
Pathophysiology of ANCA-Associated Small Vessel Vasculitis
Author
Cees G. M. Kallenberg
Publication date
01-12-2010
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 6/2010
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-010-0138-6

Other articles of this Issue 6/2010

Current Rheumatology Reports 6/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.